FDA and CE Marking for AI-Based Medical Imaging Software: A Practical Regulatory Path

Shipping AI that reads medical images is not primarily a model problem — it is a claims and evidence problem. Influrion Solutions is a software development and healthcare IT company; we see CTOs and regulatory affairs leads burn quarters when marketing language, clinical validation, and submission strategy disagree. This guide is a practical path for AI-based medical imaging Software as a Medical Device (SaMD) across the US FDA and EU CE marking under the Medical Device Regulation (MDR) — not legal advice, and not a substitute for your notified body or counsel.

If you treat regulatory work as a binder you assemble after the pilot “works,” you will redesign the product under deadline pressure. The teams that move faster lock intended use, risk class, and change-control rules for the model before they scale training data or sales demos.

Start with intended use — not with the architecture diagram

Regulators classify and review what you claim the software does in clinical practice, not how impressive your transformer backbone is. Write a one-page intended-use statement that a radiologist, a hospital buyer, and a reviewer can all parse the same way:

• Population — which patients, modalities, body parts, and care settings?
• Users — radiologists only, triage nurses, ED physicians, or fully automated routing?
• Input — DICOM series requirements, prior studies, demographics, acquisition constraints?
• Output — detection, triage score, segmentation overlay, measurement, worklist priority?
• Clinical role — second reader, concurrent reader, primary interpretation, or non-diagnostic aid?
• What you explicitly do not claim — the exclusions that keep you out of a higher risk class

Marketing copy that says “diagnoses pneumonia like a specialist” while the regulatory file says “assists prioritization of chest X-rays” is a classic failure mode. Align product, sales, clinical validation, and labeling before you freeze a validation dataset.

Quick claim-risk checklist

Claim pattern	Typical pressure on classification
Worklist prioritization with no diagnostic label	Often lower relative risk if carefully scoped
Detection / localization with overlay for clinician review	Mid-range; evidence and UI design matter
Quantitative measurement that drives therapy decisions	Higher; metrology and clinical association needed
Autonomous diagnosis without clinician confirmation	Highest scrutiny; rarely the right first product

Map risk class early (US and EU use different ladders)

You need two classification stories that share the same intended use.

United States — FDA device class and pathway choice

For imaging AI SaMD, most teams land in one of:

Pathway	When it tends to fit	What you must prove
510(k)	Substantial equivalence to a predicate with similar tech and intended use	Same intended use + similar technological characteristics, or differences that do not raise new questions of safety/effectiveness
De Novo	Novel device type with no suitable predicate, but reasonable assurance of safety/effectiveness	Special controls you can live with operationally
PMA	Highest risk / insufficient other pathways	Clinical evidence depth that matches Class III expectations

AI imaging products often start with a narrow intended use that supports 510(k) or De Novo, then expand indications later. Expanding claims later is normal; pretending a narrow file covers a broad commercial story is not.

European Union — MDR class and Notified Body reality

Under MDR, software classification follows Rule 11 and related guidance — clinical decision influence and severity of the healthcare situation drive class. Many AI imaging tools that influence diagnosis or treatment land in Class IIa or higher, which means a Notified Body review for CE marking, not a pure self-declaration story.

Practical EU implications for product teams:

• Budget calendar time for Notified Body queues, not only for writing the technical file
• Clinical evaluation is continuous reasoning over literature + your own data, not a single PDF dump
• General Safety and Performance Requirements (GSPR), risk management (ISO 14971), usability, and cybersecurity evidence must match the claims
• UDI, EUDAMED registration, and vigilance processes are operational systems — treat them like production services

CE marking is market access for the EU (and related markets that recognize it). It is not a mutual recognition free pass for FDA clearance, and FDA clearance is not a CE mark.

Build one evidence spine that both dossiers can reuse

Duplicating science for two regulators wastes money. Design a shared evidence spine, then fork dossier packaging.

Shared spine (build once)

1. Quality management system — ISO 13485-aligned processes for design control, CAPA, supplier control, and document control.
2. Software lifecycle — IEC 62304 (and IEC 82304-1 where applicable) with risk-based software safety classification.
3. Risk management — ISO 14971 file that ties hazards to mitigations in UI, labeling, and architecture.
4. Cybersecurity — threat model, SBOM discipline, update/patch process, and secure configuration for hospital networks.
5. Clinical performance — dataset provenance, inclusion/exclusion, ground-truth method, primary endpoints, subgroup performance, and failure modes.
6. Human factors — can the intended user correctly understand outputs and limitations under realistic workload?

Dataset and performance rules that survive review

AI imaging files fail when datasets look like research papers rather than regulated evidence:

• Representativeness — scanners, protocols, demographics, disease prevalence, and sites must match the intended use — not only the training convenience set
• Independence — test sets must be sealed from training/tuning; document patient-level splits
• Ground truth — who labeled, with what adjudication, against what reference standard?
• Subgroups — report performance where harm concentrates (rare findings, low-quality acquisitions, underrepresented populations)
• Operating point — threshold selection must be justified for clinical use, not only for leaderboard AUC
• Drift plan — how you detect performance change when scanners or prevalence shift

If you cannot explain how a false negative reaches a patient and how labeling/UI mitigates it, you are not ready for submission — regardless of model accuracy.

US-specific moves: labeling, PCCP, and change control

FDA reviewers care deeply about what changes after clearance. For machine learning devices, a Predetermined Change Control Plan (PCCP) — where appropriate for your product — can describe how you will modify the model within bounded specifications without a new submission for every weight update.

Even without a formal PCCP, you need an internal change-control matrix:

Change type	Example	Typical regulatory instinct
Cosmetic UI	Color theme, non-clinical layout	Often lower — still document
Performance improvement within same intended use	Retrain on more in-distribution data, same claims	May need assessment / PCCP coverage
New anatomy or modality	Add CT after XR-only clearance	Usually new submission / expanded indication
New clinical claim	From triage to diagnostic detection	New submission
New users or care setting	From radiology suite to ED autonomous use	New submission / major reassessment

Also plan for:

• Labeling — indications, contraindications, warnings, performance summary a clinician can use
• Cybersecurity submissions expectations — architecture, update mechanism, vulnerability handling
• Real-world monitoring — complaint handling tied to model versioning

Do not ship continuous learning in production hospitals without a regulated change story. “We retrain weekly from customer data” is a GTM fantasy until QMS and labeling say otherwise.

EU-specific moves: clinical evaluation, PMS, and vigilance

CE marking under MDR expects a living system:

• Clinical Evaluation Report (CER) that argues benefit-risk for your exact claims
• Post-Market Surveillance (PMS) plan and, where required, Post-Market Clinical Follow-up (PMCF)
• Vigilance — serious incident reporting timelines and field safety corrective actions
• Technical documentation structured so a Notified Body can audit design history, verification, and validation

AI-specific friction points in EU files:

• Explainability expectations vary; clarity of limitations and user responsibility always matters
• Training data governance (consent, lawful basis, anonymization quality) intersects GDPR — keep privacy and device files consistent
• Substantial updates to algorithms can trigger reassessment — versioning and configuration management must be audit-ready

Side-by-side: what differs in practice

Topic	US FDA focus	EU CE (MDR) focus
Gatekeeper	FDA review / clearance or approval	Notified Body (for most Class IIa+) + manufacturer CE mark
Classification driver	Device class + pathway (510(k)/De Novo/PMA)	MDR rules (incl. Rule 11) + clinical risk
Core question	Safe & effective for labeled use; substantial equivalence or De Novo special controls	Conformity to GSPR; clinical evaluation & QMS adequacy
AI change management	PCCP / new submission logic	Significant change assessment vs technical file / NB
Market listing	Device listing / registration practices	UDI + EUDAMED (as applicable)
After launch	MDR (Medical Device Reporting), complaints, recalls	Vigilance, PMS/PMCF, FSCA

Use the table in planning workshops. Do not invent a “global dossier” that papers over these differences with one vague clinical study.

A practical 90-day sequencing plan (pre-submission)

This is an engineering-and-regulatory operating plan, not a guarantee of clearance timelines.

Days 1–30 — freeze the product identity

• Finalize intended use + exclusions; kill conflicting marketing language
• Draft US pathway hypothesis and EU class hypothesis with regulatory counsel
• Stand up design controls: requirements, risk file skeleton, software safety class
• Define clinical endpoints and dataset protocol (sites, truthing, stats analysis plan)
• Decide model update policy: locked model at launch vs PCCP-style bounded updates

Days 31–60 — generate evidence you can defend

• Collect/curate validation data under the protocol (not ad-hoc hospital dumps)
• Run verification (software) and validation (clinical performance) with version pins
• Complete cybersecurity threat model and update/patch runbooks
• Draft labeling and IFU; run formative usability on the real UI
• Build a single source of truth for model cards / version history linked to QMS records

Days 61–90 — package and pressure-test

• Assemble FDA submission outline (or Q-Sub questions if you need FDA feedback first)
• Assemble MDR technical documentation outline and Notified Body readiness gaps
• Hold a red-team review: “What claim did sales make last month that is not in the file?”
• Define post-market metrics, complaint codes, and escalation owners
• Create a change-control RACI so ML engineers cannot silently ship weights

If you are resource-constrained, narrow the intended use rather than starving evidence. A cleared narrow product that expands later beats a broad claim that never ships.

Buyer and hospital diligence questions you should already answer

Enterprise imaging buyers will ask variants of:

1. What exactly is cleared/CE-marked — and what is still “research mode”?
2. Which model version is in production, and how are updates approved?
3. How do you handle out-of-distribution studies and low-quality acquisitions?
4. Where does PHI go for training, support, and monitoring?
5. What is the human oversight model in the reading workflow?
6. Can you produce performance by subgroup relevant to our patient mix?

If your sales engineers cannot answer without improvising, regulatory and commercial are still misaligned.

Common pitfalls (and cheaper alternatives)

Pitfall	Why it hurts	Better move
Pilot metrics ≠ submission metrics	Hospitals love AUC slides; regulators want labeled endpoints under intended use	Design the pilot as a dress rehearsal for the pivotal analysis
Continuous learning without controls	Breaks design freeze and labeling	Lock model; use PCCP/bounded updates later
US-only file then “translate” to EU	Misses CER, NB, and PMS structure	Shared spine + jurisdiction-specific packaging from day 30
Overclaiming in demos	Creates off-label use risk and dossier contradictions	Script demos to cleared/CE intended use only
Ignoring integration reality	PACS/RIS workflow failures become safety complaints	Validate with DICOM routing, hanging protocols, and worklist UX

FAQ

Does FDA clearance mean I can CE mark without more work?

No. Evidence can transfer, but MDR conformity assessment, clinical evaluation structure, and post-market systems are distinct. Plan both tracks explicitly if you sell in both regions.

Can we CE mark first and do FDA later?

Yes, many companies sequence markets. Just do not assume EU class and clinical evaluation automatically dictate the FDA pathway — reverse-map claims carefully when you enter the US.

Is a research model deployed in a hospital “not a device”?

Intended use and how it is presented/used matter more than your internal “research” label. If clinicians rely on it for clinical decisions in real care, treat it as regulated until counsel says otherwise.

Do we need a clinical trial for every imaging AI product?

Not always. Study design depends on claims, novelty, and risk. Some products rely on well-controlled retrospective performance studies plus human factors; higher-risk claims may need prospective clinical evidence. Decide with regulatory experts against your exact indications.

What should engineering own vs regulatory own?

Engineering owns design controls, software lifecycle evidence, cybersecurity implementation, and reproducible training/eval pipelines. Regulatory owns classification strategy, submission authorship, and Notified Body/FDA communication. Clinical owns truthing standards and benefit-risk narrative. Shared ownership without a RACI is how files stall.

Closing

FDA and CE marking for AI-based medical imaging software reward teams that treat claims, evidence, and change control as product features. Start with a crisp intended use, build a shared QMS and performance spine, then fork US and EU packaging without pretending the pathways are identical. If you want help aligning imaging workflows, DICOM integration, and regulated software delivery practices with that plan, contact Influrion Solutions — we build healthcare IT software with those constraints in mind.